SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
FBIO reported Third Quarter 2026 results. The price and volatility reaction is pending.
FBIOearnings

Earnings reactions, page 2

Fortress Biotech, Inc. (FBIO) Q3 FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • Total net revenue increased approximately 9% to $19.2 million for the third quarter of 2026, compared to $17.6 million for the third quarter of 2025.
  • Net product revenue from marketed dermatology products was $18.9 million for the third quarter of 2026, compared to $17.0 million for the third quarter of 2025.
  • Consolidated research and development expenses were $1.7 million for the third quarter of 2026, compared to $0.2 million for the third quarter of 2025.
  • Consolidated selling, general and administrative costs were $17.8 million for the third quarter of 2026, compared to $17.4 million for the third quarter of 2025.
  • Consolidated net loss attributable to common stockholders was $7.9 million, or $0.23 per share basic and diluted, for the third quarter of 2026, compared to net income attributable to common stockholders of $3.7 million, or $0.13 per share basic and $0.11 per share diluted, for the third quarter of 2025.
  • Consolidated cash and cash equivalents totaled $152.2 million as of September 30, 2026, compared to $79.4 million as of December 31, 2025.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-13 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →